Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TOCOSOL(R) Paclitaxel
TOCOSOL Paclitaxel · 2 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| TOCOSOL Paclitaxel | EXPERIMENTAL | TOCOSOL Paclitaxel administered weekly at 120mg/mm2 |
| Name | Type | Description |
|---|---|---|
| TOCOSOL(R) Paclitaxel | DRUG | - |
| TOCOSOL Paclitaxel | DRUG | - |
Inclusion Criteria: * Female patient with histologic diagnosis of breast carcinoma * Stage IV (M1) disease * No prior cytotoxic chemotherapy regimen for treatment of metastatic breast cancer * Adult (18 years of age or older) patients * Adequate hematologic function (ANC \>=1500 cells/mm3 and plate...
TOCOSOL Paclitaxel is an investigational small-molecule oncology drug developed by Achieve Life Sciences, Inc. It has been studied in Phase 2 clinical trials as a treatment for breast cancer and for bladder neoplasms, including transitional cell carcinoma of the urothelium. It is also known as TOCOSOL(R) Paclitaxel.
TOCOSOL Paclitaxel has been studied in Phase 2 trials for metastatic breast cancer as initial treatment and for metastatic or locally advanced unresectable transitional cell carcinoma of the urothelium, a form of bladder cancer. It is investigational and has not been established as an approved therapy for these indications.
TOCOSOL Paclitaxel is developed by Achieve Life Sciences, Inc., which trades under the ticker QUIT. The company sponsored the Phase 2 clinical program evaluating the drug in breast cancer and urothelial cancer.
TOCOSOL Paclitaxel is in Phase 2 development. Its clinical program includes completed Phase 2 trials in metastatic breast cancer and in transitional cell carcinoma of the urothelium. The drug is investigational and is not approved for marketing in these indications.
TOCOSOL Paclitaxel has been evaluated in two completed Phase 2 trials. NCT00096668 studied it as initial treatment for metastatic breast cancer in 47 patients in Russia. NCT00077688 studied it in metastatic or locally advanced unresectable transitional cell carcinoma of the urothelium in 44 patients in the United States.
Yes, TOCOSOL(R) Paclitaxel is the same drug as TOCOSOL Paclitaxel. The registered trademark symbol appears in the formal name used in some trial titles and company materials, while TOCOSOL Paclitaxel is the shorter form used in general references to the same investigational oncology asset.